How Do I Co-Lead with a Challenging Partner?
Further reading:
How Co-Leaders Succeed
8 Reasons Why Co-Leaders Fail
What is a RACI chart?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Amazon (AMZN) Stock Climb on Massive Price Target Hike From UBS
July 28 - Amazon (NASDAQ:AMZN) stock climbed about 1% on Monday morning after UBS lifted its 12?month price target to $271 from $249, keeping a "Buy" rating intact. Warning! GuruFocus has detected 4 Warning Sign with AMZN. The upgrade follows UBS's decision to reverse some cuts it made three months ago when it foresaw deeper tariff?driven headwinds. The firm now expects 2026 gross merchandise value to rise about 2%, and it bumped gross profit forecasts by the same margin. UBS also nudged up its 2027 GMV and profit estimates by roughly 2%, and it raised advertising?segment forecasts for both years by about 3%. It left its AWS growth outlook at 16% for Q2 2025. The revised outlook translates into a 1% boost in 2026 revenue and a 5% jump in EBIT, with 2027 revenue up 0.1% and EBIT climbing 7%. UBS raised its 2025 CapEx forecast to $112 billion from $107 billion after Amazon's recent disclosure. Meanwhile, Google (NASDAQ:GOOGL) secured a $1.2 billion cloud deal with ServiceNow (NYSE:NOW), and Amazon is winding down its Shanghai AI lab amid tensions. Reports also suggest Jeff Bezos is eyeing a CNBC acquisition, and he met with former President Donald Trump at the White House. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
Biologic Therapeutics Market to Hit $794.5 Billion by 2029
"Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies, Gene and Cell Therapies, and Innovative Vaccines" BOSTON, July 28, 2025 /PRNewswire/ -- According to the latest study from BCC Research, "Biologic Therapeutic Drugs: Technologies and Global Markets" is projected to increase from $499.2 billion in 2024 to reach $794.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 9.7% from 2024 through 2029. This report provides a comprehensive analysis of the global market for biologic therapeutic drugs, segmented by product type (such as mAbs vaccines, and cell and gene therapies), source (mammalian, microbial, others), application (oncology, autoimmune, and infectious diseases), and region (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). It explores key market trends, challenges, and ESG developments, and examines the emerging technologies shaping the industry. The report also includes a competitive landscape analysis with market share rankings and detailed profiles of leading companies. This report is particularly relevant now due to the growing demand for innovative therapies and the rapid advances in regenerative medicine. Increased investments and intensified research activities are accelerating the development of biologic drugs, while a surge in product approvals is expanding treatment options in many medical fields. These factors are collectively driving significant growth in the biologics market, making timely insights into trends, challenges, and competitive dynamics more critical than ever. The factors driving the market's growth include: Growing Demand for Biologics: Biologics are increasingly favored due to their high efficacy, targeted action, and ability to treat complex diseases like cancer and autoimmune disorders. Patients and healthcare providers are turning to these advanced therapies for better outcomes and fewer side effects. Rising Investments in Biopharmaceuticals: The biopharma sector is seeing a surge in funding from pharmaceutical companies, investors, and governments. These investments support research, clinical trials, and manufacturing infrastructure, accelerating the development and availability of biologic drugs. Product Development Collaborations and Agreements: Collaborations between biotech firms and large pharmaceutical companies are common, enabling shared expertise, reduced costs, and faster product development. Licensing deals and joint ventures also help expand market reach and streamline commercialization. Transition Toward Personalized Medicines: Biologics are central to the shift toward personalized medicine, where treatments are tailored to individual genetic profiles. Advances in genomics and diagnostics enable more precise therapies, reducing trial-and-error in treatment. Aging Population and the Prevalence of Chronic Diseases: An aging global population is leading to a higher incidence of chronic diseases such as diabetes, cancer, and arthritis. Biologics offer effective long-term treatment options for these conditions, making them essential in managing the health needs of older adults. Request a sample copy of the global market for biologic therapeutic drugs report. Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $456.9 billion Market size forecast $794.5 billion Growth rate CAGR of 9.7% for the forecast period of 2024-2029 Segments covered Type, Source, Application, Region Regions covered North America, Europe, Asia-Pacific, Rest of the World(South America and the Middle East and Africa). Countries covered U.S., Canada, Mexico, U.K., Germany, France, Spain, Italy,China, India, Japan, Australia. Market drivers Growing Demand for Biologics Rising Investments in Biopharmaceuticals Product Development Collaborations andAgreements Transition Toward Personalized Medicines Rising Aging Population and the Growing Prevalenceof Chronic Diseases Interesting facts: The biologic therapeutics market is witnessing higher number of approvals for several new therapies and an increase in biologics approvals yearly. In 2023, the market witnessed approvals for breakthrough therapies such as gene editing therapy Casgevy from CRISPR Therapeutics and Vertex Pharmaceuticals and Leqembi (lecanemab) from Eisai for Alzheimer's disease. Emerging startups Arcus Biosciences Allogene Therapeutics Astria Therapeutics Bean Therapeutics HiFiBiO Therapeutics The report addresses the following questions: 1. What is the projected size and growth rate of the market? The global market for biologic therapeutic drugs was valued at $456.9 billion in 2023 and is expected to grow at a CAGR of 9.7% from 2024 to 2029 to reach $794.5 billion by the end of 2029. 2. What factors are driving the growth of the market? The global market for biologics therapeutic drugs is growing due to the world's rising aging population and the growing prevalence of chronic diseases, increasing numbers of product launches, and high demand for personalized medicine. 3. Which market segments are covered in the report? The global market for biologics therapeutic drugs is segmented based on product type, source, application, and region. 4. Which product type segment will be dominant through 2029? The monoclonal antibodies (mAbs) segment will dominate the market through 2029. 5. Which region has the largest market share? North America holds the largest share of the market. Market leaders include: ABBVIE INC. AMGEN INC. ASTRAZENECA BRISTOL-MYERS SQUIBB CO. ELI LILLY AND CO. F. HOFFMANN-LA ROCHE LTD. GILEAD SCIENCES INC. GSK PLC. JOHNSON & JOHNSON SERVICES INC. MERCK & CO. INC. NOVARTIS AG NOVO NORDISK A/S PFIZER INC. REGENERON PHARMACEUTICALS INC. SANOFI Related reports: Antibody Drugs: Technologies and Global Markets: This report provides reviews the global antibody drug market, focusing on monoclonal antibodies (mAbs) used in treating chronic diseases like cancer and autoimmune disorders. It covers market trends, regional analysis, and key companies. Forecasts extend to 2029, highlighting growth in therapeutic applications and technological advances. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
Dutch Bros Stock Flashing Sure-Fire Bull Signal
Shares of coffee chain Dutch Bros Inc (NYSE:BROS) have been pulling back since early June, down 0.2% at $59.36 at last glance today. The stock looks due for a short-term rebound, however, as the recent price action has it running into the supportive 200-day trendline, which coincides with its year-to-date breakeven level. Per Schaeffer's Senior Quantitative Analyst Rocky White, BROS is within 0.75 of the 200-day trendline's 20-day average true range (ATR) after spending at least 80% of the last 10 days and 80% of the last two months above it. Over the past , two similar signals have occurred, and the equity was higher one month later both times with an average 21% gain. A move of similar magnitude would put Dutch Bros stock at $71.82, erasing its July losses. BROS' 14-day relative strength index (RSI) of 30.7 sits on the cusp of "oversold" territory. Plus, short interest represents 6.6% of the stock's available float, leaving plenty of pent-up buying power in the event of a bounce. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
